samedan logo
 
 
spacer
home > pmps > summer 2002 > liposomes as drug delivery systems
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Liposomes as Drug Delivery Systems

The usefulness of liposomes in pharmacy and medicine as carriers of active substances has been postulated since the early 1960s, when the phenomenon of encapsulation of some chemical compounds in lipide microspheres was recognised. However, it was only in the past few years that the objective proof of therapeutic efficacy when using this method of drug delivery was realised and the first launches of liposomal drug dosage forms took place.

Basic Information on Liposomes

Liposomes are microscopic or submicroscopic structures of 10nm to 20mm in diameter. They are made up of one or many concentrically arranged lipid bilayers constituting an envelope. The basic matter of liposomes are amphiphilic compounds having clearly separated hydrophilic and hydrophobic centres. Hydrophilic components of lipides of bilayer are directed towards aqueous phases (external and internal), whereas hydrophobic components of both lipide layers are directed towards one another, forming the internal layer of a membrane.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Piotr Slifirski, Head of the Pharmaceutical Department
at the Pharmaceutical Research Institute in Poland Dr Piotr Slifirski is a Head of Pharmaceutical Department at the Pharmaceutical Research Institute in Warsaw, Poland.
Piotr studied Pharmacy at the Academy of Medicine in Warsaw. He holds a PhD in Pharmacy from the Academy of Medicine in Wroclaw, Poland, and specialises in drugs technology.

spacer
Dr Piotr Slifirski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta").
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement